Arun Nagarajan

Dr. Arun Nagarajan

Hematology Oncology
2950 Cleveland Clinic Boulevard, 
Weston, FL 
On Staff At
Offers Telehealth
2950 Cleveland Clinic Boulevard, 
Weston, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Arun Nagarajan is a Hematologist Oncology provider in Weston, Florida. Dr. Nagarajan is rated as an Experienced provider by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Lynch Syndrome, Cholangiocarcinoma (Bile Duct Cancer), Anal Cancer, Gastroesophageal Junction Cancer, and Liver Embolization.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years.

Residency
Rush Presbyterian-St. Luke's Medical Center
Specialties
Hematology Oncology
Licenses
Internal Medicine in FL
Board Certifications
American Board Of Internal Medicine, 2004
Fellowships
University of Arkansas for Medical Sciences
Hospital Affiliations
Cleveland Clinic Martin North Hospital
Cleveland Clinic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Egil and Pauline Braathen Center/Maroone Cancer Center
2950 Cleveland Clinic Boulevard, Weston, FL 33331

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
A Randomized Phase III Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
A Phase III, Randomized, Controlled, Double-Blind Study Evaluating the Safety of Two Doses of Apixaban for Secondary Prevention of Cancer Related Venous Thrombosis in Subjects Who Have Completed at Least Six Months of Anticoagulation Therapy
Enrollment Status: Completed
Publish Date: May 18, 2025
Intervention Type: Drug
Study Drug: Apixaban
Study Phase: Phase 3
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
A Phase 1B, Randomized, Open-Label Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Cisplatin Plus Gemcitabine and PEGPH20 in Combination With Atezolizumab and Cisplatin Plus Gemcitabine Compared With Cisplatin Plus Gemcitabine in Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 3 Less Clinical Trials

26 Total Publications

Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer.
Real-world Monitoring of ctDNA Reliably Predicts Cancer Recurrence and Treatment Efficacy in Patients with Resected Stages I-III Colon Cancer.
Journal: Annals of surgery
Published: March 24, 2025
Similar Doctors
Peter J. Hosein
Elite in Pancreatic Cancer
Dr. Peter J. Hosein
Hematology Oncology | Hematology | Oncology
Elite in Pancreatic Cancer
Dr. Peter J. Hosein
Hematology Oncology | Hematology | Oncology

University Of Miami

1475 Nw 12th Ave, 
Miami, FL 
 (22.3 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Peter Hosein is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Hosein is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Pancreatic Cancer, Familial Pancreatic Cancer, Ampullary Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Hosein is currently accepting new patients.

Distinguished in Pancreatic Cancer
Dr. Antonio Ucar
Hematology Oncology | Hematology | Oncology
Distinguished in Pancreatic Cancer
Dr. Antonio Ucar
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Oncology LLC

8900 N Kendall Dr, 
Miami, FL 
 (27.6 miles away)
786-596-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Antonio Ucar is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Ucar is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Pancreatic Cancer, Anal Cancer, Familial Colorectal Cancer, and Colorectal Cancer. Dr. Ucar is currently accepting new patients.

Distinguished in Pancreatic Cancer
Dr. Santiago Aparo
Hematology Oncology | Hematology | Oncology
Distinguished in Pancreatic Cancer
Dr. Santiago Aparo
Hematology Oncology | Hematology | Oncology

Baptist Health Medical Group Oncology LLC

9555 Sw 162 Ave, 
Miami, FL 
 (28.4 miles away)
786-467-2000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Santiago Aparo is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Dr. Aparo is rated as a Distinguished provider by MediFind in the treatment of Pancreatic Cancer. His top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Familial Colorectal Cancer, and Lynch Syndrome. Dr. Aparo is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nagarajan's expertise for a condition
ConditionClose
    View All 7 Distinguished Conditions
    View All 18 Advanced Conditions
    View All 81 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile